{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:34:51Z","timestamp":1789425291209,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["219744"],"award-info":[{"award-number":["219744"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03433-y","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T07:59:30Z","timestamp":1766563170000},"page":"710-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Challenges in Evaluating Clinical Remission in Severe Asthma: Insights from the Mayo Clinic"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4551-6559","authenticated-orcid":false,"given":"Kaiser","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijita","family":"Deb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Corbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Kelloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safak","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Barman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"3433_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/resp.14520","volume":"28","author":"PA Shah","year":"2023","unstructured":"Shah PA, Brightling C. Biologics for severe asthma. Which, when and why? Respirology. 2023;28:709\u201321.","journal-title":"Respirology"},{"key":"3433_CR2","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2024. https:\/\/ginasthma.org\/2024-report\/. Accessed Sept 2024."},{"key":"3433_CR3","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jaip.2024.01.044","volume":"12","author":"WW Busse","year":"2024","unstructured":"Busse WW, Chupp G, Corbridge T, Stach-Klysh A, Oppenheimer J. Targeting asthma remission as the next therapeutic step toward improving disease control. J Allergy Clin Immunol Pract. 2024;12:894\u2013903.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3433_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5414\/ALX02445E","volume":"8","author":"M Lommatzsch","year":"2024","unstructured":"Lommatzsch M. Asthma therapy concepts through the ages. Allergol Sel. 2024;8:1\u20135.","journal-title":"Allergol Sel"},{"key":"3433_CR5","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","volume":"39","author":"A Menzies-Gow","year":"2022","unstructured":"Menzies-Gow A, Hoyte FL, Price DB, et al. Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab. Adv Ther. 2022;39:2065\u201384.","journal-title":"Adv Ther"},{"key":"3433_CR6","doi-asserted-by":"publisher","first-page":"1150162","DOI":"10.3389\/fimmu.2023.1150162","volume":"14","author":"I Pavord","year":"2023","unstructured":"Pavord I, Gardiner F, Heaney LG, et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study. Front Immunol. 2023;14:1150162.","journal-title":"Front Immunol"},{"key":"3433_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41533-023-00330-1","volume":"33","author":"ML Levy","year":"2023","unstructured":"Levy ML, Bacharier LB, Bateman E, et al. Key recommendations for primary care from the 2022 global initiative for asthma (GINA) update. NPJ Prim Care Respir Med. 2023;33:7.","journal-title":"NPJ Prim Care Respir Med"},{"key":"3433_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/02770903.2019.1591443","volume":"57","author":"LJ Nannini","year":"2020","unstructured":"Nannini LJ. Treat to target approach for asthma. J Asthma. 2020;57:687\u201390.","journal-title":"J Asthma"},{"key":"3433_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/MCP.0000000000001068","volume":"30","author":"M Lommatzsch","year":"2024","unstructured":"Lommatzsch M. Remission in asthma. Curr Opin Pulm Med. 2024;30:325\u20139.","journal-title":"Curr Opin Pulm Med"},{"key":"3433_CR10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","volume":"131","author":"M Blaiss","year":"2023","unstructured":"Blaiss M, Oppenheimer J, Corbett M, et al. Consensus of an American college of allergy, asthma, and immunology, American academy of allergy, asthma, and immunology, and American thoracic society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol. 2023;131:782\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3433_CR11","unstructured":"US prescribing information. XOLAIR (omalizumab) for injection, for subcutaneous use. 2023. https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf. Accessed Jan 2024."},{"key":"3433_CR12","unstructured":"US prescribing information. NUCALA (mepolizumab) for injection, for subcutaneous use. 2023. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL-IFU-COMBINED.PDF. Accessed Jan 2024."},{"key":"3433_CR13","unstructured":"US prescribing information. CINQAIR (reslizumab) injection, for intravenous use. 2020. https:\/\/www.cinqair.com\/globalassets\/cinqair\/prescribinginformation.pdf. Accessed Jan 2024."},{"key":"3433_CR14","unstructured":"US prescribing information. FASENRA (benralizumab) injection, for subcutaneous use. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761070s000lbl.pdf. Accessed Jan 2024."},{"key":"3433_CR15","unstructured":"US prescribing information. DUPIXENT (dupilumab) injection, for subcutaneous use. 2023. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761055lbl.pdf. Accessed Jan 2024."},{"key":"3433_CR16","unstructured":"US prescribing information. TEZSPIRE (tezepelumab-ekko) injection, for subcutaneous use. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761224s001lbl.pdf. Accessed Jan 2024."},{"key":"3433_CR17","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189\u201397.","journal-title":"N Engl J Med"},{"key":"3433_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100464","volume":"13","author":"GW Canonica","year":"2020","unstructured":"Canonica GW, Blasi F, Paggiaro P, et al. Oral corticosteroid sparing with biologics in severe asthma: a remark of the severe asthma network in Italy (SANI). World Allergy Organ J. 2020;13:100464.","journal-title":"World Allergy Organ J"},{"key":"3433_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010182","author":"CY Chen","year":"2023","unstructured":"Chen CY, Wu KH, Guo BC, et al. Personalized medicine in severe asthma: from biomarkers to biologics. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms25010182.","journal-title":"Int J Mol Sci"},{"key":"3433_CR20","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1080\/02770903.2024.2441887","volume":"62","author":"J Correa-Borit","year":"2025","unstructured":"Correa-Borit J, Laorden D, Arnalich Montiel V, Quirce S, Dom\u00ednguez-Ortega J. Is it possible to achieve remission in severe asthma? Retrospective analysis of a four-year response in a real-life cohort treated with mepolizumab. J Asthma. 2025;62:794\u20137.","journal-title":"J Asthma"},{"key":"3433_CR21","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3390\/biomedicines12050960","volume":"12","author":"D Bagnasco","year":"2024","unstructured":"Bagnasco D, Bondi B, Caminati M, et al. Evaluation of clinical remission in best-performing severe asthmatic patients treated for three years with mepolizumab. Biomedicines. 2024;12:960.","journal-title":"Biomedicines"},{"key":"3433_CR22","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1016\/j.jaip.2024.08.033","volume":"12","author":"C Crimi","year":"2024","unstructured":"Crimi C, Nolasco S, Noto A, et al. Long-term clinical and sustained remission in severe eosinophilic asthma treated with mepolizumab: the REMI-M study. J Allergy Clin Immunol Pract. 2024;12:3315\u201327.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3433_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107528","volume":"222","author":"A Breslavsky","year":"2024","unstructured":"Breslavsky A, Al Qaied A, Tsenter P, et al. Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy. Respir Med. 2024;222:107528.","journal-title":"Respir Med"},{"key":"3433_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13223-023-00863-7","volume":"20","author":"KR Chapman","year":"2024","unstructured":"Chapman KR, Cogger K, Arthurs E, et al. Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study. Allergy Asthma Clin Immunol. 2024;20:11.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3433_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.imu.2022.101139","volume":"36","author":"A Turchin","year":"2023","unstructured":"Turchin A, Masharsky S, Zitnik M. Comparison of BERT implementations for natural language processing of narrative medical documents. Inf Med Unlocked. 2023;36:101139.","journal-title":"Inf Med Unlocked"},{"key":"3433_CR26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.58227","volume":"9","author":"T Wagner","year":"2020","unstructured":"Wagner T, Shweta F, Murugadoss K, et al. Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis. Elife. 2020;9:e58227.","journal-title":"Elife"},{"key":"3433_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00151","volume":"8","author":"H Barman","year":"2024","unstructured":"Barman H, Venkateswaran S, Santo AD, et al. Identification and characterization of immune checkpoint inhibitor-induced toxicities from electronic health records using natural language processing. JCO Clin Cancer Inform. 2024;8:e2300151.","journal-title":"JCO Clin Cancer Inform"},{"key":"3433_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2021.100255","volume":"2","author":"K Murugadoss","year":"2021","unstructured":"Murugadoss K, Rajasekharan A, Malin B, et al. Building a best-in-class automated de-identification tool for electronic health records through ensemble learning. Patterns. 2021;2:100255.","journal-title":"Patterns"},{"key":"3433_CR29","doi-asserted-by":"crossref","unstructured":"Beltagy I, Lo K, Cohan A. SciBERT: a pretrained language model for scientific text. arXiv. (2019) 1903.10676.","DOI":"10.18653\/v1\/D19-1371"},{"key":"3433_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100793","volume":"34","author":"C Pawlowski","year":"2021","unstructured":"Pawlowski C, Venkatakrishnan AJ, Ramudu E, et al. Pre-existing conditions are associated with COVID-19 patients\u2019 hospitalization, despite confirmed clearance of SARS-CoV-2 virus. EClinicalMedicine. 2021;34:100793.","journal-title":"EClinicalMedicine"},{"key":"3433_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/dom.12129","volume":"16","author":"AJ Garber","year":"2014","unstructured":"Garber AJ. Treat-to-target trials: uses, interpretation and review of concepts. Diabetes Obes Metab. 2014;16:193\u2013205.","journal-title":"Diabetes Obes Metab"},{"key":"3433_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3\u201315.","journal-title":"Ann Rheum Dis"},{"key":"3433_CR33","unstructured":"Disease WHON, Mental Health Cluster. Innovative care for chronic conditions: building blocks for action: global report: World Health Organization. 2002."},{"key":"3433_CR34","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1001\/jama.288.14.1775","volume":"288","author":"T Bodenheimer","year":"2002","unstructured":"Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002;288:1775\u20139.","journal-title":"JAMA"},{"key":"3433_CR35","volume":"15","author":"IM Dighriri","year":"2023","unstructured":"Dighriri IM, Alnughaythir AI, Albesisi AA, et al. Efficacy and safety of mepolizumab in the management of severe eosinophilic asthma: a systematic review. Cureus. 2023;15:e49781.","journal-title":"Cureus"},{"key":"3433_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jclinepi.2021.01.008","volume":"134","author":"KJ Lee","year":"2021","unstructured":"Lee KJ, Tilling KM, Cornish RP, et al. Framework for the treatment and reporting of missing data in observational studies: the treatment and reporting of missing data in observational studies framework. J Clin Epidemiol. 2021;134:79\u201388.","journal-title":"J Clin Epidemiol"},{"key":"3433_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.5009\/gnl230272","volume":"18","author":"MK Kim","year":"2024","unstructured":"Kim MK, Rouphael C, McMichael J, Welch N, Dasarathy S. Challenges in and opportunities for electronic health record-based data analysis and interpretation. Gut Liver. 2024;18:201\u20138.","journal-title":"Gut Liver"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03433-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03433-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03433-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:10Z","timestamp":1771268590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03433-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3433"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03433-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kaiser Lim was a consultant for nference, which received payment from GSK to conduct this study. Arijita Deb, Thomas Corbridge, and Judy Kelloway are employed by GSK and hold financial equities in GSK. Lydia Lee was a fellow at GSK at the time of study and is currently employed by Boehringer Ingelheim (Boehringer Ingelheim has no connection to this study). Safak Simsek was employed by nference when this study was conducted, which received payment from GSK to conduct this study. Mithun Manoharan, Hannah Barman, and Tyler Wagner are employees of nference, which received payment from GSK to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Aggregated data that omit patient identification were used, informed consent and ethics committee approval was not required, and authorization by the Institutional Review Board was waived. Conference had access to patient data through a partnership with the Mayo Clinic; therefore, permission was not required to access the database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}